Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Association Between Fetal Safety Outcomes and Exposure to Local Podophyllotoxin During Pregnancy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Genetic, Clinical, and Environmental Factors Associated With Persistent Atopic Dermatitis in Childhood

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association of Disease Severity With Skin Microbiome and Filaggrin Gene Mutations in Adult Atopic Dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Allergen Concerns and Popular Skin Care Products

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Anabolic-androgenic steroids and the risk of imprisonment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Mossman-Pacey Paradox

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Risk of stroke subsequent to infective endocarditis: A nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Importance: Podophyllotoxin is an antimitotic agent primarily used in the local treatment of anogenital warts. Data that enable the assessment of the fetal safety of podophyllotoxin use during pregnancy are lacking.

Objective: To investigate the association between local podophyllotoxin exposure during pregnancy and risk of adverse fetal outcomes.

Design, Setting, and Participants: This cohort study obtained individual-level pregnancy data from various nationwide registries in Denmark from the study period of January 1, 1997, through December 31, 2016, resulting in a cohort of 1 650 649 pregnancies. Pregnancies with multiple records on overlapping dates and pregnancy records with implausible or missing information on gestational age were excluded. Local podophyllotoxin-exposed pregnancies were compared with unexposed pregnancies and matched in a 1:10 ratio according to propensity scores on a wide set of baseline characteristics. Five distinct study cohorts were constructed, one for each outcome analysis. Sensitivity analyses included a comparison of podophyllotoxin-exposed pregnancies with pregnancies with podophyllotoxin use only before pregnancy onset. Data analyses were performed from April 27, 2019, to June 26, 2019.

Exposures: Filled prescription for local podophyllotoxin.

Main Outcomes and Measures: Primary outcomes were major birth defects and spontaneous abortions. Secondary outcomes were preterm births, small-for-gestational-age (SGA) size, and stillbirths. Logistic regression was used to estimate the prevalence odds ratios (ORs) of major birth defects, preterm births, and SGA size, and Cox proportional hazards regression modeling was used to estimate hazard ratios (HRs) of spontaneous abortions and stillbirths.

Results: This study included 9229 pregnancies (mean [SD] maternal age at pregnancy onset, 27.7 [5.2] years) for the analyses of major birth defects and 18 590 pregnancies (mean [SD] maternal age at pregnancy onset, 26.4 [6.0] years) for the analyses of spontaneous abortions. Among the podophyllotoxin-exposed pregnancies, 29 infants (3.5%) were diagnosed with major birth defects, compared with 286 (3.4%) among the unexposed pregnancies. A total of 141 podophyllotoxin-exposed pregnancies (8.3%) ended in spontaneous abortion, compared with 1626 (9.6%) among the unexposed pregnancies. No statistically significant associations were found between podophyllotoxin exposure during pregnancy and major birth defects (prevalence odds ratio [OR], 1.02 95% CI, 0.69-1.50), spontaneous abortions (HR, 0.87; 95% CI, 0.73-1.04), preterm births (prevalence OR, 1.08; 95% CI, 0.86-1.35), SGA size (prevalence OR, 1.01; 95% CI, 0.85-1.22), or stillbirths (HR, 0.58; 95% CI, 0.18-1.86). Sensitivity analyses of the primary outcomes achieved similar results.

Conclusions and Relevance: Findings from this study suggest that podophyllotoxin use during pregnancy may be safe, as it did not appear to be associated with an increased risk of adverse fetal outcomes. These findings may help guide clinicians, patients, and drug regulatory authorities when prescribing podophyllotoxin.

OriginalsprogEngelsk
TidsskriftJAMA Dermatology
ISSN2168-6068
DOI
StatusE-pub ahead of print - 8 jan. 2020

ID: 58933417